OBJECTIVES: HTAinSite is an on-line, subscription-based database of all NICE Technology Appraisals (TAs). It includes information relating to submitted evidence, appraisal process and final decision and enables assessment of associated trends. METHODS: An academic steering group designed and agreed the data extraction protocol. A team of reviewers conducted the initial data extraction, which was validated by a second reviewer. Historical extraction is complete, with on-going TAs extracted on a monthly basis. RESULTS: A total of 181 TAs have been extracted to date, 5 of which were terminated, resulting in 176 complete TAs relating to 326 technologies. Of these, 53% were awarded a restricted decision, 32% were fully recommended and 16% rejected. Of the three most commonly appraised disease areas (cancer, cardiovascular (CVS), central nervous system (CNS); CVS technologies were least commonly rejected by NICE (3% vs.21% for cancer and 17% for CNS). Of the four most commonly used assessment groups (Sheffield, York, Southampton and Birmingham); technologies assessed by Sheffield were most commonly rejected (28%) and those by York were least commonly rejected (4%). Technologies supported by a patient submission were less commonly rejected than those without (15% vs.29%). A total of 35 TAs (20%) resulted in an appeal, no appeals were upheld entirely, all appeals were upheld partially. HTAinSite also allows detailed analysis of individual TAs and cross-comparison between TAs as well as identifying trends between submitted evidence (acquisition costs, budget impact, cost-effectiveness and clinical effectiveness) and final outcome. These additional analyses will be further explored in the poster and preliminary results will also be updated. CONCLUSIONS: HTAinSite is a useful tool for anyone interested in understanding the relationship between submitted evidence and ultimate NICE decision. The HTAinSite format may be useful for other HTA bodies, depending on the public availability of relevant information.